Media Advisory

Monday, June 3, 2024

NIH scientists develop AI tool to predict how cancer patients will respond to immunotherapy

What

In a proof-of-concept study, researchers at the 最新麻豆视频 (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone鈥檚 cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells. The machine-learning model may help doctors determine if immunotherapy drugs are effective for treating a patient鈥檚 cancer. The study, published June 3, 2024, in Nature Cancer, was led by researchers at the and Memorial Sloan Kettering Cancer Center in New York. NCI is part of the 最新麻豆视频. 聽

Currently, two predictive biomarkers are approved by the Food and Drug Administration for use in identifying patients who may be candidates for treatment with immune checkpoint inhibitors. The first is tumor mutational burden, which is the number of mutations in the DNA of cancer cells. The second is PD-L1, a tumor cell protein that limits the immune response and is a target of some immune checkpoint inhibitors. However, these biomarkers do not always accurately predict response to immune checkpoint inhibitors. Recent machine-leaning models that use molecular sequencing data have shown value in predicting response, but this kind of data is expensive to obtain and not routinely collected.

The new study details a different kind of machine-learning model that makes predictions based on five clinical features that are routinely collected from patients: a patient鈥檚 age, cancer type, history of systemic therapy, blood albumin level, and blood neutrophil-to-lymphocyte ratio, a marker of inflammation. The model also considers tumor mutational burden, assessed through sequencing panels. The model was constructed and evaluated using data from multiple independent data sets that included 2,881 patients treated with immune checkpoint inhibitors across 18 solid tumor types.

The model accurately predicted a patient鈥檚 likelihood of responding to an immune checkpoint inhibitor and how long they would live, both overall and before the disease returned. Notably, the researchers said, the model was also able to identify patients with low tumor mutational burden who could still be treated effectively with immunotherapy.

The researchers noted that larger prospective studies are needed to further evaluate the AI model in clinical settings. They have made their AI model, called Logistic Regression-Based Immunotherapy-Response Score (LORIS), publicly available at . The tool estimates the likelihood of a patient responding to immune checkpoint inhibitors based on data on the six variables described above.

The study was co-led by Eytan Ruppin, M.D., Ph.D., of NCI鈥檚 Center for Cancer Research and Luc G. T. Morris, M.D., of Memorial Sloan Kettering Cancer Center. The work was spearheaded by Tiangen Chang, Ph.D., and Yingying Cao, Ph.D., of Dr. Ruppin鈥檚 group at NCI鈥檚 Center for Cancer Research.

Who

Eytan Ruppin, M.D., Ph.D., Center for Cancer Research, 最新麻豆视频 Cancer Institute

The Study

鈥淟ORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features鈥 appears June 3, 2024, in Nature Cancer.

About the 最新麻豆视频 Cancer Institute (NCI): NCI leads the 最新麻豆视频 Cancer Program and NIH鈥檚 efforts to dramatically reduce the prevalence of cancer and improve the lives of people with cancer. NCI supports a wide range of cancer research and training extramurally through grants and contracts. NCI鈥檚 intramural research program conducts innovative, transdisciplinary basic, translational, clinical, and epidemiological research on the causes of cancer, avenues for prevention, risk prediction, early detection, and treatment, including research at the NIH Clinical Center鈥攖he world鈥檚 largest research hospital. Learn more about the intramural research done in NCI鈥檚 . For more information about cancer, please visit the NCI website at or call NCI鈥檚 contact center at 1-800-4-CANCER (1-800-422-6237).

About the 最新麻豆视频 (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health庐

###